What do we know about the safety of lipid nanoparticles in mRNA vaccines?
There have also been authorised vaccines with a similar structure, called “virosomal vaccines”, e.g. Epaxal for hepatitis A or Inflexal for influenza. Virosomes are also phospholipid vesicles that carry viral envelope proteins on their surface. We have many years of experience with these vaccines and they have a good safety profile. At present, they are no longer on the market, but this is not the result of safety concerns.
The potential toxicity of each of these novel vaccine preparations was tested in preclinical toxicity tests prior to marketing authorisation.
That from FAQ in last post
As an alternative to the virosome vaccines used up to now, other viral vectors can be used which contain genes for protective influenza proteins, so that these proteins are then expressed on the surface of the viruses. For this purpose, vaccinia or adenoviruses are used as the basis, the advantage of which is that they induce an efficient immune response of cytotoxic T cells that attack infected cells efficiently
(GRAPHIC) V. ALTOUNIAN/SCIENCE; (IMAGES) CASALINO ET AL., ACS CENT SCI., 6(10), 1722, (2020); CONSURF SERVER; 7K3J; FEIG LAB/6XDC; PAUL EHRLICH INST.; EUROPEAN MOLECULAR BIOLOGY LAB; MAX PLANCK INSTITUTE OF BIOPHYSICS; D. ELLIS/UW; PDB 6VXX;
News 
Market Data 
Discover 
